Mor DE - Search Results

1

Evidence of native α-synuclein conformers in the human brain.

Gould N, Mor DE, Lightfoot R, Malkus K, Giasson B, Ischiropoulos H. Gould N, et al. Among authors: mor de. J Biol Chem. 2014 Mar 14;289(11):7929-34. doi: 10.1074/jbc.C113.538249. Epub 2014 Jan 28. J Biol Chem. 2014. PMID: 24474688 Free PMC article.

2

Dynamic structural flexibility of α-synuclein.

Mor DE, Ugras SE, Daniels MJ, Ischiropoulos H. Mor DE, et al. Neurobiol Dis. 2016 Apr;88:66-74. doi: 10.1016/j.nbd.2015.12.018. Epub 2015 Dec 31. Neurobiol Dis. 2016. PMID: 26747212 Free PMC article. Review.

3

Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.

Mor DE, Tsika E, Mazzulli JR, Gould NS, Kim H, Daniels MJ, Doshi S, Gupta P, Grossman JL, Tan VX, Kalb RG, Caldwell KA, Caldwell GA, Wolfe JH, Ischiropoulos H. Mor DE, et al. Nat Neurosci. 2017 Nov;20(11):1560-1568. doi: 10.1038/nn.4641. Epub 2017 Sep 18. Nat Neurosci. 2017. PMID: 28920936 Free PMC article.

4

The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease.

Mor DE, Ischiropoulos H. Mor DE, et al. J Exp Neurosci. 2018 Mar 8;12:1179069518761360. doi: 10.1177/1179069518761360. eCollection 2018. J Exp Neurosci. 2018. PMID: 29559809 Free PMC article.

5

The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Mor DE, Daniels MJ, Ischiropoulos H. Mor DE, et al. Mov Disord. 2019 Feb;34(2):167-179. doi: 10.1002/mds.27607. Epub 2019 Jan 11. Mov Disord. 2019. PMID: 30633814 Free PMC article. Review.

6

Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms.

Chen M, Mor DE. Chen M, et al. Among authors: mor de. Int J Mol Sci. 2023 Apr 13;24(8):7205. doi: 10.3390/ijms24087205. Int J Mol Sci. 2023. PMID: 37108366 Free PMC article. Review.

7

Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria.

Mor DE, Sohrabi S, Kaletsky R, Keyes W, Tartici A, Kalia V, Miller GW, Murphy CT. Mor DE, et al. Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26438-26447. doi: 10.1073/pnas.2009838117. Epub 2020 Oct 6. Proc Natl Acad Sci U S A. 2020. PMID: 33024014 Free PMC article.

8

Mitochondrial hyperactivity as a potential therapeutic target in Parkinson's disease.

Mor DE, Murphy CT. Mor DE, et al. Transl Med Aging. 2020;4:117-120. doi: 10.1016/j.tma.2020.07.007. Epub 2020 Aug 12. Transl Med Aging. 2020. PMID: 33178902 Free PMC article.

9

GAIT-GM integrative cross-omics analyses reveal cholinergic defects in a C. elegans model of Parkinson's disease.

McIntyre LM, Huertas F, Morse AM, Kaletsky R, Murphy CT, Kalia V, Miller GW, Moskalenko O, Conesa A, Mor DE. McIntyre LM, et al. Among authors: mor de. Sci Rep. 2022 Feb 28;12(1):3268. doi: 10.1038/s41598-022-07238-9. Sci Rep. 2022. PMID: 35228596 Free PMC article.

10

Heparan sulfate proteoglycans mediate prion-like α-synuclein toxicity in Parkinson's in vivo models.

Chen M, Vincent J, Ezeanii A, Wakade S, Yerigenahally S, Mor DE. Chen M, et al. Among authors: mor de. Life Sci Alliance. 2022 Jul 5;5(11):e202201366. doi: 10.26508/lsa.202201366. Print 2022 Nov. Life Sci Alliance. 2022. PMID: 35790300 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters